Spiro Ring System Patents (Class 514/462)
  • Patent number: 10285955
    Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: May 14, 2019
    Assignee: AF Chemicals, LLC
    Inventor: Michael Kelner
  • Patent number: 9980926
    Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 29, 2018
    Assignee: AF CHEMICALS, LLC
    Inventor: Michael Kelner
  • Patent number: 9872912
    Abstract: A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: January 23, 2018
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin, Yi-Wen Chou, Mao-Hsuan Huang
  • Patent number: 9868718
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 16, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
  • Patent number: 9682060
    Abstract: Apoptosis is generally believed to be a process that requires several hours, in contrast to non-programmed forms of cell death that can occur in minutes. Our findings challenge the time-consuming nature of apoptosis. We describe herein the discovery and characterization of a small molecule, named Raptinal, which initiates intrinsic pathway caspase-dependent apoptosis within minutes, in multiple different cell lines. Comparison to a mechanistically diverse panel of apoptotic stimuli reveals Raptinal-induced apoptosis proceeds with unparalleled speed. The rapid phenotype enabled identification of the critical roles of mitochondrial voltage-dependent anion channel function, mitochondrial membrane potential/coupled respiration, and mitochondrial complex I, III and IV function for apoptosis induction. Use of Raptinal in whole organisms demonstrates its utility to study apoptosis in vivo for a variety of applications.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: June 20, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Karson S. Putt, Rahul Palchaudhuri
  • Patent number: 9611244
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 4, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Patent number: 9586942
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 7, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Patent number: 9533966
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Patent number: 9415053
    Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 16, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventor: Klaus Benke
  • Patent number: 9381178
    Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: July 5, 2016
    Assignee: AF CHEMICALS LLC
    Inventor: Michael Kelner
  • Patent number: 9283228
    Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: March 15, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventor: Klaus Benke
  • Patent number: 9221783
    Abstract: The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for alleviation of muscle spasm, such that it is promising for preventing or treating various diseases associated with muscle spasm.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: December 29, 2015
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9073819
    Abstract: Embodiments of the present disclosure provide compositions including ketamine analogs, salts, and disalts, pharmaceutical compositions including ketamine analogs, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 7, 2015
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jahanshah Amin, Kirpal S. Bisht, Meghanath Gali
  • Publication number: 20150133414
    Abstract: It was determined whether SNPs in SLC4A5 are associated with salt sensitivity of blood pressure (BP). Subjects consumed an isocaloric constant diet with a randomized order of 7 days low Na+ (10 mmol/d) and 7 days high Na+ (300 mmol/d) intake. Salt sensitivity was defined as a ?7 mm Hg increase in mean arterial pressure (MAP). 35 polymorphisms in 17 candidate genes were assayed. Association analyses with salt sensitivity revealed three variants that associated with salt sensitivity, two in SLC4A5 (rs7571842, rs10177833; P<0.001), and one in GRK4 (rs1801058; P=0.020). Paradoxical changes in blood pressure in response to changes in salt intake were also found associated with a SNP for DRD2 (rs6276). In conclusion, SLC4A5 variants are strongly associated with salt sensitivity of BP in Caucasian and a DRD2 SNP is a marker for paradoxical response to salt intake.
    Type: Application
    Filed: April 22, 2013
    Publication date: May 14, 2015
    Applicant: University of Virginia Patent Foundation
    Inventors: Robin A. Felder, Robert M. Carey, John E. Jones, Pedro A. Jose, Scott M. Williams
  • Publication number: 20150133297
    Abstract: The present invention relates to new antifungal compositions and their use in the treatment of agricultural products.
    Type: Application
    Filed: April 25, 2013
    Publication date: May 14, 2015
    Inventors: Jacobus Stark, Eva Louise Wilhelmine Sack
  • Publication number: 20150126436
    Abstract: The present invention provides a method of treatment of Scedosporium spp.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 7, 2015
    Applicant: BIODIEM LIMITED
    Inventors: Julie Phillips, Tania Sorrell, Sharon Chen
  • Publication number: 20150080220
    Abstract: Compositions including a highly branched alpha-D-glucan or modified forms thereof and a solute compound are described herein. The compositions can provide increased water solubility and/or increased rate of dissolution for the solute compound. The compositions can also provide increased stability for the solute compound. Methods for preparing and using compositions including a solute compound and a highly branched alpha-D-glucan are also described.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 19, 2015
    Inventors: Yuan Yao, Jingmin Zhang
  • Patent number: 8980943
    Abstract: Disclosed are substituted 2-oxaspiro[5.5]undec-8-ene derivatives of formula (I) and their use as odorants. This disclosure relates furthermore to a method of their production and flavor and fragrance compositions comprising them.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: March 17, 2015
    Assignee: Givaudan S.A.
    Inventors: Andreas Goeke, Yue Zou
  • Publication number: 20150073045
    Abstract: The invention relates to a novel compound of the formula or pharmaceutically acceptable salts thereof as well as pharmaceutical, nutraceutical, and botanical drug compositions and therapeutic methods related thereto. In certain embodiments, the compounds are used for the treatment of abnormal cell growth, hyperproliferative disorders, and inflammatory diseases in mammals. In other embodiments, the invention encompasses methods to isolate and synthesize the compounds.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicant: CORNELL UNIVERSITY
    Inventors: Kathryn J. Chavez, Eloy Rodriguez, Frank Schroeder, James A. Flanders
  • Publication number: 20150065547
    Abstract: An esterified cellulose ether comprises (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein the cellulose ether has anhydroglucose units joined by 1-4 linkages and has methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that the esterified cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydroglucose units are substituted with methyl groups such that [s23/s26?0.2*MS(hydroxyalkyl)] is 0.
    Type: Application
    Filed: October 24, 2012
    Publication date: March 5, 2015
    Applicant: Dow Global Technologies LLC
    Inventors: Robert L. Schmitt, Robert L. Sammler, Meinolf Brackhagen, Oliver Petermann, Roland Adden, Nicholas S. Grasman, Steven J. Guillaudeu
  • Publication number: 20150065548
    Abstract: A liquid composition comprises an organic diluent and at least one cellulose ether having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that hydroxyl groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.29 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group. The liquid composition can be used for preparing a solid dispersion of an active ingredient in a cellulose ether.
    Type: Application
    Filed: April 8, 2013
    Publication date: March 5, 2015
    Inventors: Roland Adden, Robert L. Sammler, Meinolf Brackhagen, Nicholas S. Grasman, Oliver Petermann, Steven J. Guillaudeu
  • Publication number: 20150057238
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • Patent number: 8901038
    Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, and CKE have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or fungicides. Moreover, the invention relates to selectively herbicidal compositions comprising, firstly, the biphenyl-substituted cyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising in particular biphenyl-substituted cyclic ketoenols through the addition of ammonium or phosphium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or nematicides and/or acaricides and/or fungicides and/or for preventing unwanted plant growth.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: December 2, 2014
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Stefan Lehr, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Chieko Ueno, Arnd Voerste, Elmar Gatzweiler, Ines Heinemann, Ulrich Görgens
  • Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Publication number: 20140296210
    Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Craig C. Garner, Fabian J. Fernandez
  • Patent number: 8846568
    Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from the class of the tetronic or tetramic acids, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: September 30, 2014
    Assignee: Bayer CropScience AG
    Inventors: Peter Jeschke, Robert Velten, Heike Hungenberg, Reiner Fischer, Wolfgang Thielert
  • Patent number: 8841294
    Abstract: The invention relates to insecticidal and acaricidal mixtures comprising certain cyclic ketoenols and agonists or antagonists of nicotinic acetylcholine receptors for protecting plants against attack by pests.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: September 23, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Reiner Fischer, Christoph Erdelen
  • Publication number: 20140271783
    Abstract: A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents.
    Type: Application
    Filed: October 15, 2012
    Publication date: September 18, 2014
    Inventors: Rodolfo Pinal, Bo Zhou, Andrew Otte
  • Publication number: 20140274930
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Evelyne Dietrich, Carl Poisson, Michel Gallant, Stephanie Lessard, Bingcan Liu, Sanjoy Kumar Das, Yeeman Ramtohul, Thumkunta Jagadeeswar Reddy, Julien Martel, Frederic Vallee, Jean-Francois Lévesque
  • Publication number: 20140256731
    Abstract: Pleuromutilin derivative compounds of the following formula, and uses thereof for the treatment of diseases mediated by microbes, are disclosed:
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Applicant: NABRIVA THERAPEUTICS AG
    Inventors: Rosemarie MANG, Werner HEILMAYER, Rudolf BADEGRUBER, Dirk B. STRICKMANN, Rodger NOVAK, Mathias FERENCIC, Atchyuta Rama Chandra Murty BULUSU
  • Publication number: 20140228375
    Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
    Type: Application
    Filed: March 12, 2014
    Publication date: August 14, 2014
    Applicant: Anavex Life Sciences Corp.
    Inventor: Alexandre Vamvakides
  • Publication number: 20140221473
    Abstract: Embodiments of the present disclosure provide compositions including ketamine analogues, salts, and disalts, pharmaceutical compositions including ketamine analogues, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Application
    Filed: June 29, 2012
    Publication date: August 7, 2014
    Inventors: Jahanshah Amin, Kirpal S. Bisht, Meghanath Gali
  • Patent number: 8778895
    Abstract: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: July 15, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Christian Funke, Thomas Bretscheneider, Reiner Fischer, Rüdiger Fischer, Heike Hungenberg, Wolfram Andersch, Wolfgang Thielert, Anton Kraus
  • Publication number: 20140171498
    Abstract: This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from Leucas stelligera, being useful for prevention, treatment, inhibition or controlling growth and proliferation of mycobacterial activity in mammals. The invention further discloses process for isolation of the fractions containing the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: June 19, 2014
    Applicant: Council of Scientific & Indusrtial Reasearch
    Inventors: Swati Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
  • Patent number: 8722072
    Abstract: The present invention relates to active ingredient combinations which are composed of a known dihydrofuranone derivative on the one hand and of other known active pesticidal ingredients on the other hand, and are suitable for controlling animal pests from the families of the Aleyrodidae, Thripidae, Psyllidae and Agromyzidae, and also, more particularly, from the order of the Acari. The invention also relates to combinations which consist of the abovementioned active ingredient combinations on the one hand and of beneficial species on the other hand and which are suitable for controlling animal pests.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 13, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Reiner Fischer, Veronica Companys, Estuardo Jara Dominguez, Heike Hungenberg, Peter Meisner
  • Publication number: 20140128458
    Abstract: The invention relates to a novel compound of the formula or pharmaceutically acceptable salts thereof as well as pharmaceutical, nutraceutical, and botanical drug compositions and therapeutic methods related thereto. In certain embodiments, the compounds are used for the treatment of abnormal cell growth, hyperproliferative disorders, and inflammatory diseases in mammals. In other embodiments, the invention encompasses methods to isolate and synthesize the compounds.
    Type: Application
    Filed: October 1, 2013
    Publication date: May 8, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Kathryn J. Chavez, Eloy Rodriguez, Frank Schroeder, James A. Flanders
  • Publication number: 20140121246
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Application
    Filed: October 15, 2013
    Publication date: May 1, 2014
    Applicant: Metabolex, Inc.
    Inventors: Dong Fang Shi, Jiangao Song, Christopher J. Rabbat, Jingyuan Ma, Aaron Novack, Imad Nashashibi, Xin Chen
  • Patent number: 8691863
    Abstract: The present invention relates to the use of active substance combinations which consist firstly of known cyclic ketoenols and secondly of further known insecticidal active substances, for controlling animal pests from the stink bug family (Pentatomidae).
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: April 8, 2014
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Konrad Kemper, Jürgen Kühnhold, Xavier Alain Marie Van Waetermeulen, Francisco Leonel Junior Lozano
  • Publication number: 20140088158
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicant: SANOFI
    Inventors: Josef PERNERSTORFER, Heinz-Werner KLEEMANN, Matthias SCHAEFER, Alena SAFAROVA, Marcel PATEK
  • Publication number: 20140088092
    Abstract: The present invention relates to the use of active substance combinations for controlling animal pests, for example, from the chinch bug family (Lygaeidae), as well as animal pests that has shown resistance to pyrethroids.
    Type: Application
    Filed: March 8, 2013
    Publication date: March 27, 2014
    Applicant: Bayer CropScience LP
    Inventors: Jeffrey A. MICHEL, Kenneth A. KUKOROWSKI
  • Patent number: 8673968
    Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: March 18, 2014
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
  • Patent number: 8664265
    Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: March 4, 2014
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Arno Appavoo Enose, Harish Kumar Madan, Sumit Madan, Anupam Trehan, Puneet Tyagi, Vinod Kumar Arora
  • Patent number: 8652997
    Abstract: The invention relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide) and at least one further insecticide of the tetronic acid derivatives group and optionally one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: February 18, 2014
    Assignee: Bayer CropScience AG
    Inventors: Lutz Assmann, Pete Howard Davies, Michael Klüken, Karl-Wilhelm Münks, Peter Dahmen, Heike Hungenberg
  • Publication number: 20140045696
    Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, A, B, D and G have the meanings given above, to a plurality of processes and intermediates for their preparation, and to their use as pesticides and/or herbicides and/or fungicides. The invention also relates to selective herbicidal compositions comprising, firstly, the halogen-substituted spirocyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising, in particular, halogen-substituted spirocyclic ketoenols, through the addition of ammonium salts or phosphonium salts and optionally penetrants, to the corresponding compositions, to processes for producing them and to their application in crop protection as pesticides and/or fungicides and/or for preventing unwanted plant growth. The invention also relates to substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.
    Type: Application
    Filed: February 14, 2012
    Publication date: February 13, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Thomas Bretschneider, Reiner Fischer, Stefan Lehr, Elmar Gatzweiler, Ulrich Gõrgens, Isolde Häuser-Hahn, Ines Heinemann, Arnd Voerste
  • Patent number: 8632795
    Abstract: The present invention relates to a device in the form of a container made of a polymer material, which container has one or more sealed chambers, each of which comprise a liquid pheromone comprising 2-ethyl-1,6-dioxaspiro[4,4]nonane, methyl 2,4-decadiene-carboxylate and at least one alcohol selected among 2-methylbut-3-en-2-ol and 2-methylbut-3-yn-2-ol, where at least 50% of the area of the walls forming the chambers have a wall thickness in the range of from 0.1 to 1 mm and the polymer material which forms the chamber is at least in those areas an uncoated vinyl acetate/ethylene copolymer with a vinyl acetate content in the range of from 10 to 17% by weight. The invention also relates to a method of combating and for monitoring the swarming behavior of the species Pityogenes chalcographus, generally also referred to as spruce wood engraver or six-dentated bark beetle.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: January 21, 2014
    Assignee: BASF SE
    Inventors: Thomas Zühlke, Jürgen Jentzsch, Ulf Baier, Hansjochen Schroeter
  • Patent number: 8628794
    Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: January 14, 2014
    Assignee: Novartis AG
    Inventor: Ute Isele
  • Patent number: 8618084
    Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: December 31, 2013
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Aleksander Hinek, Thomas F. Mitts
  • Patent number: 8618096
    Abstract: Methods and compositions for treating disease caused by increased iron levels are disclosed Fluoregenic compounds and methods of using the same are also described.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: December 31, 2013
    Assignee: The Regents of the University of California
    Inventors: Adam Renslo, Sumit Mahajan
  • Publication number: 20130338222
    Abstract: The present invention relates to methods and compositions comprising spirodiclofen and/or spiromesifen for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as Varroa destructor in bee, preferably honey bee, colonies, and to the treatment of varroatosis in bees.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 19, 2013
    Applicant: SYNGENTA CROP PROTECTION LLC
    Inventor: Andre Fougeroux
  • Publication number: 20130324580
    Abstract: The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on miliusane compounds. The present invention also includes its preparation and application method for treating cancer.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 5, 2013
    Applicant: HONG KONG BAPTIST UNIVERSITY
    Inventor: Hongjie ZHANG